HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada UK Head On COVID-19 Impact, Local Growth Strategy And OTC Brand Innovation

Executive Summary

Exclusive: HBW Insight talks to Stada executive vice-president Roger Scarlett-Smith on the progress of the company's ambitious growth strategy, the impact of the coronavirus and its new innovation centre in Yorkshire, England.

You may also be interested in...



Stada's Nature’s Aid Submits CBD Novel Food Application

HBW Insight speaks exclusively to Chris Morrey, CEO of Stada's UK Nature's Aid subsidiary, about the company's experiments with CBD and its recently submitted EU novel food application. 

Stada Grabs GSK Brands In Key EU Markets

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales in excess of €100m.

Stada Snaps Up Supplements In Philippines

Stada has added to its consumer healthcare business in the Philippines by acquiring the Fern C range of vitamin C food supplements.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel